ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

• DOI: 10.1210/jc.2018-00163
• Publication Date: 2018-05-24T18:28:43Z
• Authors: Henry G Bone; Felicia Cosman; Paul D Miller; Gregory C Williams; Gary Hattersley; Ming-yi Hu; Lorraine A Fitzpa...; Bruce Mitlak; Socrates Papapoulos; René Rizzoli; Robin K Dore; John P Bilezikian; Kenneth G Saag
• Keywords: Bone remodeling

In women with postmenopausal osteoporosis, we investigated the effects of 24 months treatment alendronate (ALN) following 18 abaloparatide (ABL) or placebo (PBO).Women who completed ABL PBO in ACTIVE were eligible to receive up ALN. We evaluated incidence vertebral and nonvertebral fractures changes bone mineral density (BMD) during entire 43-month period from baseline end ACTIVExtend for 24-month extension only.Five hundred fifty-eight ACTIVE's group 581 its (92% completers) enrolled. During full period, 0.9% evaluable ABL/ALN experienced a new radiographic fracture vs 5.6% PBO/ALN group, an 84% relative risk reduction (RRR, P < 0.001). Kaplan-Meier rates other reported types significantly lower (all 0.05). Gains BMD achieved further increased ACTIVExtend. For only, RRR was 87% (P = Adverse events similar between groups. A supplemental analysis regulatory authorities found no hip five group.Eighteen followed by ALN reduced vertebral, nonvertebral, clinical, major osteoporotic BMD. Sequential appears be effective option at osteoporosis-related fractures.